Related Experiment Video
Updated: Dec 27, 2025

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in
Jun Ding1,2,3,4, Kangdi Xu2,3,4,5, Suwan Sun6,7,8
1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Abstract:
Inhibitors of the CDK family of proteins have been approved for the treatment of a variety of tumours; however, the development of new drugs administered in combination with CDK inhibitors is expected to improve the therapeutic effect. We identified the function of suppressor of cytokine signalling 1 (SOCS1) in hepatocellular carcinoma (HCC) cell models and the xenograft mouse model. When SOCS1 expression was artificially upregulated, HCC cell lines were arrested at the G1-S transition in the cell cycle. Interestingly, during this process, total CyclinD1 protein increased, but the effective proportion decreased. We found that the deficiency of CyclinD1 in the nucleus is probably due to the decrease in the stability of nuclear CyclinD1 caused by the ubiquitin-based degradation of P21, thus inhibiting the progression of the cell cycle to S phase. After P21 expression was increased, the levels of the component that inactivates CyclinD1 decreased as expected. It showed that P21 has a partial promoting effect on cancer. SOCS1 is a good indicator of prognosis, tumour size and long-term survival after resection. SOCS1 is expected to become a drug target in combined with CDK family inhibitors.
Insights
Suppressor of cytokine signalling 1 (SOCS1) inhibits hepatocellular carcinoma (HCC) progression by arresting the cell cycle. Upregulating SOCS1 may enhance combined therapies with CDK inhibitors for improved cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- Cyclin-dependent kinase (CDK) inhibitors are approved for various cancers.
- Developing combination therapies with CDK inhibitors can improve therapeutic outcomes.
- The role of suppressor of cytokine signalling 1 (SOCS1) in hepatocellular carcinoma (HCC) requires further elucidation.
Purpose of the Study:
- To investigate the function of SOCS1 in hepatocellular carcinoma (HCC) cell and mouse models.
- To explore the mechanism by which SOCS1 influences cell cycle progression in HCC.
- To evaluate SOCS1 as a potential prognostic biomarker and therapeutic target in HCC.
Main Methods:
- Utilized HCC cell line models and a xenograft mouse model.
- Artificially upregulated SOCS1 expression to observe its effects.
- Analyzed cell cycle progression, protein levels (CyclinD1, P21), and protein stability.
- Assessed SOCS1 as a prognostic indicator for tumour size and patient survival.
Main Results:
- Artificial upregulation of SOCS1 expression induced G1-S cell cycle arrest in HCC cell lines.
- Increased SOCS1 led to elevated total CyclinD1 but decreased effective CyclinD1 proportion.
- P21-mediated degradation of nuclear CyclinD1 was identified as a mechanism for cell cycle inhibition.
- Increased P21 expression correlated with decreased levels of CyclinD1-inactivating components, suggesting a partial cancer-promoting role for P21.
- SOCS1 expression levels correlated with favourable prognosis, smaller tumour size, and better long-term survival.
Conclusions:
- SOCS1 plays a crucial role in inhibiting HCC cell cycle progression.
- SOCS1 acts as a potential prognostic biomarker for HCC.
- SOCS1 is a promising therapeutic target for combination therapy with CDK inhibitors in HCC treatment.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules
Positive Regulator Molecules
Negative Regulator Molecules
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System

